Polyarteritis nodosa is an autoimmune disease that affects arteries. Common areas affected include the muscles, joints, intestines (bowels), nerves, kidneys, and skin. Diagnosis of polyarteritis nodosa is confirmed by a biopsy of involved tissue or angiography. Treatment is directed toward decreasing the inflammation of the arteries.
Some people respond promptly to therapy and can taper off treatment over many months. Others require long-term treatment. The outlook for patients with polyarteritis nodosa depends on the degree of damage to affected organs and the response to treatments. For those patients with underlying hepatitis B infection, eradication of the virus is essential for optimal outcome.
In individual organs, polyarteritis nodosa can have the following effects:
There is no way to prevent most cases of polyarteritis nodosa.
Being vaccinated against hepatitis B, and avoiding activities that increase the risk of hepatitis, such as sharing needles during intravenous drug use or having unprotected sex, may prevent hepatitis-related polyarteritis nodosa.
The treatment of polyarteritis nodosa (PAN) has improved dramatically. Previously, untreated PAN was usually fatal within weeks to months, with mortality often associated with kidney failure, cardiac complications, or GI complications. Therefore, early diagnosis and treatment are critical in PAN.
High dose steroids and cyclophosphamide are often used to get the inflammation under control (remission induction). Once under control treatment is often continued for 12 months with low dose treatment and then can be stopped in some patients.
Patients with hepatitis B virus infection will need specific treatment for the virus infection with anti-viral drugs, usually under specialist care.
Image Courtesy: Getty
Read more articles on Polyarteritis Nodosa.
A lot of people believe that osteoarthritis is a disease that gets worse with each passing day.read more
If you are well enough to be looked after at home, your prognosis is very good.read more